Education + Advocacy = Change

Click a topic below for an index of articles:

New-Material

Home

Alternative-Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

 

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”



 
  

 

 

The Co-infection of

HIV/AIDS and Hepatitis B and C:

 The Socio-Economic Impact on the

State of Florida

http://www.theaidsinstitute.org/downloads/hepc.doc

Prepared For: The Florida Department Of Health

Bureau of HIV/AIDS

 

Prepared By: The Center for Public Policy Research and Ethics

The AIDS Institute

The AIDS Institute Administrative Center · P.O. Box 16705 · Tampa, Florida 33687-6705 Phone (813) 232-5886 · Toll Free In Florida (800) 779-4898 · Fax (813) 232-0857
theaidsinstitute.org

HIV/AIDS: The United States

Tier I

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

60

540,000

$34,000

$18,360

Between

30

270,000

$20,000

$5,400

Well

10

90,000

$14,000

$1,260

Total

100

900,000

N/A

$25,020

 

 

 

 

 

 

 

 

 

 

Tier II

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

20

180,000

$34,000

$6,120

Between

60

540,000

$20,000

$10,800

Well

20

180,000

$14,000

$2,520

Total

100

900,000

N/A

$19,440

 

 

 

 

 

 

 

 

 

 

Tier III

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

10

90,000

$34,000

$3,060

Between

30

270,000

$20,000

$5,400

Well

60

540,000

$14,000

$7,560

Total

100

900,000

N/A

$16,020

*Assumes treatment for 900,000 individuals.               

*Calculations based on costs reported by (Kaiser Family Foundation, 2000 and Saag, 2002)

 

While this model was created for purely illustrative methods and remains simplistic, it encompasses a "blue sky" theory in assumptions.  The one very striking calculation, however, is the obvious difference in cost for a "healthier" population, as opposed to a "weaker" or at a more advanced disease state population.  These calculations argue for more early intervention and early treatment.  By providing that more individuals are kept healthy, almost 36% or $9,000,000,000 can be saved in expenditures.

Florida’s costs could be projected in a similar manner to the national figures, but would be based on a smaller subset of 95,000 infected individuals estimated by the Florida Department of Health.  Other costs not included in the calculations for both include the indirect costs discussed previously.  

 

HIV/AIDS: Florida

 

Tier I

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

60

57,000

$34,000

$1,938

Between

30

28,500

$20,000

$570

Well

10

9,500

$14,000

$133

Total

100

95,000

N/A

$2,641

 

 

 

 

 

 

 

 

 

 

Tier II

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

20

19,000

$34,000

$646

Between

60

57,000

$20,000

$1,140

Well

20

19,000

$14,000

$266

Total

100

95,000

N/A

$2,052

 

 

 

 

 

 

 

 

 

 

Tier III

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

10

9,500

$34,000

$323

Between

30

28,500

$20,000

$570

Well

60

57,000

$14,000

$798

Total

100

95,000

N/A

$1,691

**Assumes treatment for 95,000 individuals.

*Calculations based on costs reported by (Kaiser Family Foundation, 2000 and Saag, 2002)

Based on the previous calculations related to HIV/AIDS mono-infection, the following tables represent the additional cost of treatment for HCV.  The CDC estimates a 25% co-infection rate between HIV/AIDS and HCV (CDC, 2002).  However, the model used previously can be repeated, adding the HCV treatment cost estimate of $15,000 into the cost per patient per year (PPPY) for HIV/AIDS along the disease state estimates to calculate the impact of HCV treatment costs on HIV/AIDS costs.  Again, this model is merely illustrative and must be considered a snapshot, especially when taking into consideration the inherent differences between the ongoing and eventually finite (until death) HIV/AIDS treatment and the HCV treatment (6 months to 12 months for one course).  It is for this reason that HCV treatments cannot be annualized. 

 

HIV/HCV Co-infection: The United States

Tier I

 

 

 

 

Disease State

%

# of People

Cost PPPY

Total Cost (in millions)

Advanced

60

135,000

$49,000

$6,615

Between

30

67,500

$35,000

$2,362.5

Well

10

22,500

$29,000

$652.5

Total

100

225,000

N/A

$9,630

 

 

 

 

 

 

 

 

 

 

Tier II

 

 

 

 

Disease State

%

# of People